Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature. (2023)
Journal Article
Taylor, L., Wade, P. K., Johnson, J. E., Aldighieri, M., Morlando, S., Di Leva, G., …Coyle, B. (2023). Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature. Cancers, 15(4), Article 1086. https://doi.org/10.3390/cancers15041086

Therapy resistance represents an unmet challenge in the treatment of medulloblastoma. Accordingly, the identification of targets that mark drug-resistant cell populations, or drive the proliferation of resistant cells, may improve treatment strategie... Read More about Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature..

UC.183, UC.110, and UC.84 Ultra-Conserved RNAs Are Mutually Exclusive with miR-221 and Are Engaged in the Cell Cycle Circuitry in Breast Cancer Cell Lines. (2021)
Journal Article
Corrà, F., Crudele, F., Baldassari, F., Bianchi, N., Galasso, M., Minotti, L., …Volinia, S. (2021). UC.183, UC.110, and UC.84 Ultra-Conserved RNAs Are Mutually Exclusive with miR-221 and Are Engaged in the Cell Cycle Circuitry in Breast Cancer Cell Lines. Genes, 12(12), Article 1978. https://doi.org/10.3390/genes12121978

In the human genome, there are about 600 ultra-conserved regions (UCRs), long DNA sequences extremely conserved in vertebrates. We performed a large-scale study to quantify transcribed UCR (T-UCR) and miRNA levels in over 6000 cancer and normal tissu... Read More about UC.183, UC.110, and UC.84 Ultra-Conserved RNAs Are Mutually Exclusive with miR-221 and Are Engaged in the Cell Cycle Circuitry in Breast Cancer Cell Lines..

A KRAS-responsive long non-coding RNA controls microRNA processing (2021)
Journal Article
Shi, L., Magee, P., Fassan, M., Sahoo, S., Leong, H. S., Lee, D., …Garofalo, M. (2021). A KRAS-responsive long non-coding RNA controls microRNA processing. Nature communications, 12, Article 2038. https://doi.org/10.1038/s41467-021-22337-3

Wild-type KRAS (KRASWT) amplification has been shown to be a secondary means of KRAS activation in cancer and associated with poor survival. Nevertheless, the precise role of KRASWT overexpression in lung cancer progression is largely unexplored. Her... Read More about A KRAS-responsive long non-coding RNA controls microRNA processing.

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells (2021)
Journal Article
Buzzetti, M., Morlando, S., Solomos, D., Mehmood, A., Cox, A. W., Chiesa, M., …Di Leva, G. (2021). Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells. Scientific reports, 11, Article 5374. https://doi.org/10.1038/s41598-021-84082-3

Medulloblastoma (MB) is the most common aggressive paediatric brain tumour and, despite the recent progress in the treatments of MB patients, there is still an urgent need of complementary or alternative therapeutic options for MB infants. Cyclin Dep... Read More about Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells.

Telomerase inhibition, telomere attrition and proliferation arrest of cancer cells induced by phosphorothioate ASO-NLS conjugates targeting hTERC and siRNAs targeting hTERT (2020)
Journal Article
Diala, I., Shiohama, Y., Fujita, T., Kotake, Y., Demonacos, C., Krstic-Demonacos, M., …Fujii, M. (2020). Telomerase inhibition, telomere attrition and proliferation arrest of cancer cells induced by phosphorothioate ASO-NLS conjugates targeting hTERC and siRNAs targeting hTERT. Nucleosides, Nucleotides and Nucleic Acids, 39(1-3), 407 - 425. https://doi.org/10.1080/15257770.2020.1713357

Telomerase activity has been regarded as a critical step in cellular immortalization and carcinogenesis and because of this, regulation of telomerase represents an attractive target for anti-tumor specific therapeutics. Recently, one avenue of cancer... Read More about Telomerase inhibition, telomere attrition and proliferation arrest of cancer cells induced by phosphorothioate ASO-NLS conjugates targeting hTERC and siRNAs targeting hTERT.